type here...
type here...
START FREE TRIAL

Healthcare

Technology & AIHealthcareM&AConsumer & RetailEnergyMedia & Entertainment

Pfizer Takes On Eli Lilly & Novo: Who Gets OUTPLAYED in the Obesity Arms Race?

Healthcare Ishan Majumdar -
Pfizer just released mid-stage data from its Metsera-acquired obesity drug showing 12.3% weight loss at 28 weeks with monthly dosing. It’s the company’s first...

UnitedHealth CRASHES After Shocking Medicare Ruling — The Fallout Explained!

Healthcare Ishan Majumdar -
When a 0.09% number sends $96 billion out the window, you know something serious just happened. On January 27, the Centers for Medicare &...
spot_imgspot_img

Boston Scientific Penumbra Acquisition: The $15 Billion Gamble That Could Dominate Neurovascular Markets

Healthcare Ishan Majumdar -
If you're wondering what Boston Scientific (NYSE:BSX) has been up to lately, buckle up. On January 15, the medtech...

AbbVie Trump Investment Deal: How Medicaid Cuts Bought Regulatory Peace!

Healthcare Ishan Majumdar -
AbbVie (NYSE:ABBV) just made a bold move—and the stakes are massive. The company agreed to invest $100 billion into...

Merck Revolution Medicines Acquisition: The $30 Billion Pipeline Gamble That Could Pay Off

Healthcare Ishan Majumdar -
Merck (NYSE:MRK) is making headlines again, this time for reportedly circling Revolution Medicines (NASDAQ:RVMD) in what could be one...

Niagen NR Patent Acquisition Unlocks Massive Pharma Potential—But There’s a Catch!

Healthcare Ishan Majumdar -
If you blinked, you may have missed one of the more intriguing biotech moves of the year. Niagen Bioscience...

BioMarin Amicus Acquisition: A $4.8 Billion Bet on Rare Disease Domination

Healthcare Ishan Majumdar -
BioMarin Pharmaceutical (NASDAQ:BMRN) just made its boldest move in years—unveiling a $4.8 billion all-cash acquisition of Amicus Therapeutics. The...

Eli Lilly Adverum Acquisition Could Reshape Gene Therapy!

Healthcare Ishan Majumdar -
Eli Lilly (NYSE:LLY) isn’t slowing down. After a quarter filled with blockbuster drug launches, accelerated global uptake of Mounjaro...
Load more

Pfizer Takes On Eli Lilly & Novo: Who Gets OUTPLAYED in the Obesity Arms Race?

Healthcare Ishan Majumdar -
Pfizer just released mid-stage data from its Metsera-acquired obesity drug showing 12.3% weight loss at 28 weeks with monthly...

UnitedHealth CRASHES After Shocking Medicare Ruling — The Fallout Explained!

Healthcare Ishan Majumdar -
When a 0.09% number sends $96 billion out the window, you know something serious just happened. On January 27,...

Boston Scientific Penumbra Acquisition: The $15 Billion Gamble That Could Dominate Neurovascular Markets

Healthcare Ishan Majumdar -
If you're wondering what Boston Scientific (NYSE:BSX) has been up to lately, buckle up. On January 15, the medtech...

AbbVie Trump Investment Deal: How Medicaid Cuts Bought Regulatory Peace!

Healthcare Ishan Majumdar -
AbbVie (NYSE:ABBV) just made a bold move—and the stakes are massive. The company agreed to invest $100 billion into...

Merck Revolution Medicines Acquisition: The $30 Billion Pipeline Gamble That Could Pay Off

Healthcare Ishan Majumdar -
Merck (NYSE:MRK) is making headlines again, this time for reportedly circling Revolution Medicines (NASDAQ:RVMD) in what could be one...

Niagen NR Patent Acquisition Unlocks Massive Pharma Potential—But There’s a Catch!

Healthcare Ishan Majumdar -
If you blinked, you may have missed one of the more intriguing biotech moves of the year. Niagen Bioscience...

BioMarin Amicus Acquisition: A $4.8 Billion Bet on Rare Disease Domination

Healthcare Ishan Majumdar -
BioMarin Pharmaceutical (NASDAQ:BMRN) just made its boldest move in years—unveiling a $4.8 billion all-cash acquisition of Amicus Therapeutics. The...

Eli Lilly Adverum Acquisition Could Reshape Gene Therapy!

Healthcare Ishan Majumdar -
Eli Lilly (NYSE:LLY) isn’t slowing down. After a quarter filled with blockbuster drug launches, accelerated global uptake of Mounjaro...

Mirum Bluejay Acquisition Unlocks Rare Disease Gold!

Healthcare Ishan M. -
Mirum Pharmaceuticals (NASDAQ:MIRM) is making big moves. In early December 2025, the company announced its plan to acquire privately...

Novartis Gene Therapy Approval: A New Multi-Billion Dollar Market?

Healthcare Ishan M. -
Novartis just scored a big win with a major Novartis gene therapy approval —and it could reshape the gene...

Johnson & Johnson Halda Acquisition: The $3.05 Billion Gamble!

Healthcare Ishan Majumdar -
Johnson & Johnson just made another big move. The company announced that it will buy Halda Therapeutics for $3.05...

Merck Cidara Acquisition: $9.2B Flu Drug Deal to Replace Keytruda

Healthcare Ishan Majumdar -
Merck isn’t waiting around for Keytruda’s patent clock to run out. On November 14, the pharma giant announced its...
Load more

Baptista Research is a financial research house focused on the U.S. markets. We cover the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms.

Company

Headlines

Pfizer Takes On Eli Lilly & Novo: Who Gets OUTPLAYED in the Obesity Arms Race?

0
Pfizer just released mid-stage data from its Metsera-acquired obesity...

Is The Devon + Coterra $21 Billion Merger About Growth — Or Running Out of Rock?

0
Devon Energy just announced a $21.4 billion all-stock acquisition...

Is Apple Outflanking Meta With This Q.AI Move?

0
Apple acquired Israeli startup Q.AI for close to $2B,...

Is Amazon’s $50 Billion OpenAI Deal Really About AI — Or Just AWS Market Share?

0
Amazon is reportedly negotiating a $50 billion investment into...

Newsletter

Get important news delivered directly to your inbox and stay connected!

Copyright © 2026 Baptista Research. All rights reserved.